Essential reading for generic drug development: How to assess the risks of "drug adsorption and residue" in dissolution automated sampling systems?

In the development and formulation screening of generic drugs, in vitro dissolution testing is a core indicator for predicting bioequivalence (BE) and establishing in vitro-in vivo correlation (IVIVC). To improve sample throughput and eliminate the time error of manual sampling at regular intervals, modern pharmaceutical laboratories have widely adopted automated dissolution sampling systems .

However, automated sampling systems introduce fluid pathways such as sampling probes, long-distance transmission lines, multi-port valves, micro-injection pumps, and online filter membranes. If rigorous scientific evaluations of "drug adsorption" and "carryover/cross-contamination" are not conducted during the initial development phase, it can easily lead to falsely low initial release points, abnormal data drift in later stages, and even distorted f2 similarity factor determination, directly delaying the generic drug application process.

Based on USP <1092> "Dissolution Procedures: Development and Validation" , FDA dissolution test guidelines and ICH Q2(R2) validation framework, this article provides generic drug development teams with a systematic evaluation strategy, experimental design, the highest standard dual-solvent warm water cleaning mechanism and key pipeline maintenance cycle recommendations.

Why is the development of generic drugs particularly sensitive to "adsorption and residue"?

1. Vulnerability of the f2 similarity factor

When comparing generic drugs with original drug reference (RLD), the dissolution rate is usually lower at the first few time points (such as 5, 10, and 15 min). If the automatic sampling system experiences an adsorption loss of 5% to 10% at this time, the two curves will diverge significantly in the early stages, directly affecting the regulatory determination that f2 is greater than or equal to 50.

2. Low-dose highly active drugs and poorly soluble drugs (BCS II/IV)

When the API concentration in the eluent is only at the microgram level (µg/mL), unsaturated active adsorption sites on the tube wall or filter membrane surface will adsorb a relatively high proportion of drugs; and when poorly soluble drugs are combined with surfactants (such as SLS, Tween-80), it is easier to form adsorption or residual films in dead corners of the pipeline.

3. Chain contamination at consecutive time points

If the system does not completely empty the dead volume after sampling point T1 (e.g., high concentration point), the residual drug will be carried into the next sampling point T2, causing distortion of the drug release rate curve.

II. Risk 1: Evaluation plan for "drug adsorption" of pipelines and filter membranes

Drug adsorption mainly occurs at two interfaces: the online filter element (Filter Membrane) and the flow path tubing (Tubing / Valves / Pump Seals) .

1. Membrane adsorption evaluation and "Discard Volume" determination

According to USP <1092>, all filter membranes must undergo static and dynamic adsorption validation:

• Experimental steps :

  1. Prepare API reference standard solutions at known concentrations (covering the low and high points of expected dissolution release concentrations, such as 20% and 100% release concentrations).

  2. The standard solution that has not been microfiltration was centrifuged or settled, and the supernatant was used as the 100% recovery standard (A_standard).

  3. The reference solution is passed through the test membrane (evaluating different materials such as PVDF, PTFE, PES, and Nylon), and the filtrate is collected in segments.

     • Section 1: 0.0 to 1.0 mL

     • Section 2: 1.0 to 2.0 mL

     • Section 3: 2.0 to 3.0 mL

     • Section 4: 3.0 to 5.0 mL

  4. The API concentration of each filtrate was measured, and the recovery rate (% Recovery) was calculated.

• Acceptance criteria :

• 
  

• The recovery rate for each stage must fall within the range of 98.0% to 102.0% (this range can be relaxed to 97.0% to 103.0% for certain low-concentration formulations).

• Determine the minimum pre-flush volume required for the filter membrane to reach adsorption saturation. If a material shows significant adsorption (< 95%) in the first 3 mL, replace it with a hydrophilic PTFE or PVDF filter membrane with lower adsorption properties.

2. Overall Adsorption Evaluation of Automated Flow Path System (Automatic vs. Manual Glass Syringe Comparison)

• Experimental steps :

  1. Add a standard solution (of known uniform concentration) at a constant temperature of 37.0°C to the dissolution vessel.

  2. Manual group (control standard) : Using a non-adsorbent all-glass injection needle, samples are manually taken at a fixed sampling depth in the cup, and the sample is immediately injected through a certified filter.

  3. Automatic assembly (system under test) : The automatic sampler is activated, and the sample is completely extracted through the automatic sampling probe, tubing, syringe pump and collection rack.

  4. Test 6 sampling channels consecutively, with each channel repeated at least 3 times.

• Judgment criteria :

• 
  

• The relative deviation (Bias) between the results of the automatic group and the manual group should be less than or equal to ±1.0% .

• The coefficient of variation (%RSD) between channels should be less than or equal to 1.5% .

III. Risk 2: Assessment plan for "sample residue and cross-contamination" (Carryover) between sampling points

The purpose of residue assessment is to verify whether the automated sampling system can completely eliminate internal residues in the flow path through the purging and rinsing mechanism when switching between different sampling time points.

1. Experimental design for cross-contamination assessment (high concentration to blank sample method)

• Experimental steps :

  1. Test solution 1 (High) : Prepare a standard solution at the highest concentration that the product may achieve (usually 120% of the labeled release concentration C_High).

  2. Test solution 2 (Blank) : Pure dissolution medium blank solution (C_Blank) without any drugs.

  3. Execution procedure :

     • Run 1 : The automatic sampling system extracts C_High and discharges it into sample bottle 1.

     • Flush circulation : Perform the standard system line purging or backflush procedure.

     • Run 2 : The automatic sampling system immediately extracts blank medium C_Blank and discharges it into sample bottle 2.

     • Run 3 : Repeat the extraction of blank medium and discharge it into sample bottle 3.

• Residue rate calculation formula :

• Acceptance criteria :

• 
  

• The carryover should be less than 0.5% ( less than 0.2% is recommended for highly active drugs).

• The residual signal detected in the blank sample vial must not exceed the limit of quantitation (LOQ).

2. Simulated continuous release ladder assessment (Step-up Test)

For extended-release formulations (ER), a simulation of the real-world dissolution concentration ramp-up over time was performed (e.g., 10% → 30% → 60% → 90% → 100%).

• Compare the linear regression slopes and intercepts of "manually injecting standards at various concentrations individually" and "automatically sampling and sequentially extracting step concentrations".

• The accuracy deviation of each point was verified to be within ±1.0% , confirming that the concentration at the previous point would not cause cumulative interference to the subsequent points.

IV. Industry-leading cleaning standard: 37.0 - 40.0°C warm water and "dual-solvent continuous cleaning method"

After each batch of dissolution tests, the automatic sampling system typically leaves high concentrations of particulate matter, high-ionic-strength salts (such as phosphates and acetates), or surfactants (such as SLS and Tween-80) inside the flow path. If only room-temperature pure water is used for rinsing, it is very easy to cause surfactant emulsion residues or salt crystal precipitation and deposition on the pipe walls and micro-valve seats , resulting in serious background contamination and valve wear in the next test.

To this end, industry-leading laboratories have established the highest cleaning standard: "Double-Solvent Sequence" combined with "Constant Temperature Cleaning at 37.0 - 40.0°C" .

1. First stage: Rinse with the "experimental solvent" (Dissolution Medium).

• Scientific Mechanism : The drug has proven optimal solubility in this dissolution medium. If the experimental medium contains surfactants (such as 0.5% to 1.0% SLS), direct water rinsing often causes a sudden drop in ionic strength, leading to localized microscopic precipitation of API on the pipe wall.

• Procedure : After the experiment, the automatic sampling system immediately uses the new solvent (blank medium) used in the experiment to perform forward and reverse flushing of the entire pipeline, using the same chemical environment to quickly remove the hydrophobic drugs and emulsion particles adsorbed on the pipe wall.

2. Second stage: Rinse thoroughly with warm purified water at 37.0-40.0°C.

• Scientific Mechanism :

  • Preventing Salt Precipitation : Phosphate buffer, commonly used in dissolution tests, exhibits a significant decrease in solubility at low temperatures. Using preheated deionized water (DI Water/WFI) at 37.0 - 40.0°C can thoroughly clean residual buffer salts from the pipe walls with maximum heat of dissolution, preventing microcrystalline wear on the valve's ceramic sealing surface.

  • Accelerated Thermal Desorption : Warm water can reduce the viscosity of the liquid and the interfacial tension, and activate the micro-movement of polymer molecules in the tube wall, which promotes the rapid desorption and discharge of trace amounts of surfactants and APIs that have penetrated into the surface of Teflon micropores.

• Implementation Standards : It is recommended to set the warm water pipeline cleaning to automatic mode, with a cleaning volume of no less than 10 to 20 mL. After cleaning, be sure to start the sterile air purging program to drain all the liquid in the pipeline into the waste liquid tank, keep the inner wall of the pipeline dry, and prevent the growth of biofilm in the pipeline.

V. Key Factors of Wear and Tear: Regular Replacement Guidelines for Teflon (PTFE/FEP) Piping

In automated sampling systems, while Teflon (PTFE/FEP) tubing possesses excellent chemical inertness and acid/alkali resistance, it is by no means a permanently replacement-free component . During long-term use, Teflon tubing will still experience the following physical and chemical aging:

1. Micro-roughness of the inner wall : Long-term flow through buffer solutions containing particulate crystals, salts, or high-flow-rate rinsing will gradually roughen the pipe wall, significantly increasing the irreversible adsorption sites of API.

2. Memory effect and residual film accumulation : Drugs that are highly lipid-soluble, highly adhesive, or contain chromophores may still penetrate or bond in trace amounts into the polymer microstructure of the tube wall after long-term use, even after dual-solvent cleaning, forming a "memory effect" that is difficult to eliminate.

3. Pipe diameter creep and increase in dead volume : Under the positive and negative pressure of the syringe pump for a long time, the threaded end of the connector or the pipe wall may undergo slight deformation and tiny gaps, resulting in an increase in dead volume and a decline in sampling accuracy.

Recommendations for regular update cycles and trigger criteria:

• Routine preventative maintenance cycle (PM) :

  • Research and Development (R&D) environment : It is recommended to replace the entire sampling tubing (including the entire flow path from the sampling needle to the valve, syringe pump and dispensing needle) every 6 to 12 months .

  • Annual Mechanical Validation (MQ) Synchronization : It is recommended to include "comprehensive replacement of all Teflon sampling tubing and joint seals" as a standard preventative maintenance procedure prior to the annual MQ/PVT validation.

• Event-Driven Replacement Criteria :

  • Project Switching : When switching from a "high-activity/difficult-to-clean drug project" to a completely new R&D project, it is strongly recommended to replace the entire piping system to avoid the risk of cross-contamination.

  • Visual abnormalities in pipelines : If pipelines show discoloration, yellowing, turbidity, crystal deposits on the inner wall, or hardened creases, they should be replaced immediately.

  • Validation deviation : If the routine blank carryover test is greater than 0.5% and cannot be improved after a dual-solvent warm water deep cleaning procedure, it is considered that the adsorption sites on the pipe wall are saturated, and the entire pipeline should be replaced immediately.

VI. Engineering Key Aspects of Hardware and Flow Path Design for Automated Sampling Systems

To eliminate adsorption and residue at the hardware source, the design details of the equipment structure are crucial:

VII. Five-Step Verification Procedure for "Adsorption and Residue" Validation Standard in Generic Drug Laboratories

Before the official batch dissolution test of generic drugs, it is recommended that the R&D and quality control departments standardize the following procedures into SOPs:

1. Step 1: Filter membrane screening and waste volume confirmation

   • Perform static immersion and dynamic filtration tests (to evaluate materials such as PVDF, PTFE, PES, and Nylon).

   • Measure the volume recovery rate of each stage and confirm the volume of the initial filtrate to be discharged (it is generally recommended to set it to 1.0 to 3.0 mL to eliminate the deviation due to unsaturated adsorption in the initial stage).

2. Step Two: Verification of Piping Dead Volume and Material Compatibility

   • Accurately calculate the total flow path volume of the system (from the tip of the sampling probe to the injection needle in the sample bottle).

   • Set the system pre-rinse volume to be greater than or equal to 1.5 to 2 times the dead volume of the flow path.

3. Step 3: Cross-residue test of high and low concentrations

   • Perform the sampling procedures for 120% API standard solution and medium blank solution in sequence.

   • The residue rate should be less than 0.5% (less than 0.2% for highly active drugs); if it exceeds the limit, it is necessary to increase the intermediate air backflushing, start the dual solvent cleaning cycle, or replace the pipeline.

4. Step 4: Implement the standard procedure for dual-solvent warm water cleaning after the test.

   • After the dissolution endpoint sampling is completed, the following procedures are executed in sequence: "backflushing of the experimental medium → rinsing with warm water at 37.0 - 40.0°C → air backflushing and venting" to prevent salt precipitation and contamination.

5. Step 5: Fully Automatic vs. Manual Effectiveness Comparison

   • Six parallel comparative tests (Auto vs. Manual) were conducted on generic drug development batches.

   • The absolute value of the difference in release rate at each time point should be less than or equal to 2.0%, and the calculated f2 value of the two dissolution curves should be greater than or equal to 90.

8. Dissolution Service Perspective (Chingwei Technology)

In the evaluation of in vitro dissolution and regulatory reporting of generic drugs, the essence of automated sampling systems is not simply "saving manpower", but rather establishing a "precise measurement platform that eliminates human variation" .

When pharmaceutical companies encounter difficulties in passing f2 tests or high initial dissolution variation coefficients (%RSD) during the research and development stage, they often spend weeks or even months repeatedly adjusting the granulation prescription or tablet compression speed. In the end, they find that the root cause of the problem is simply that the sampling pipeline has adsorbed 8% of the API , or that old and unreplaced Teflon tubing has been used and that it has only been rinsed with room temperature water during cleaning. This causes the buffer salts and trace amounts of drug to form irreversible precipitation and residues in the micro-valve .

1. Starting with Quality by Design (QbD) : In the early stages of formulation development, "automation and validation of dissolution sampling" should be listed as a prerequisite for analytical method validation. First, establish the filter membrane waste volume and pipeline adsorption curves before initiating formal prescription screening.

2. Adhering to the "dual solvent + 37.0 - 40.0°C warm water" cleaning SOP : Avoid rushing the cleaning process by using only room temperature cold water. Maintaining a high standard procedure of "first dissolving the API and emulsifier with the experimental solvent, then thoroughly disintegrating the buffer salting-out and desorbing with 37.0 - 40.0°C warm water" is the fundamental key to maintaining an ultra-low system residue rate (< 0.2%).

3. Implement a pipe wear cycle management system : Do not treat Teflon pipes as permanent components. When using them frequently during R&D (6 to 12 months), during annual maintenance (MQ/PVT), or when switching major projects, proactively replace them with brand new original-specification PTFE/FEP pipes. This ensures absolute reliability of the data throughout the year at extremely low consumable costs.

4. The hardware architecture employs fully inert materials and features backflushing cleaning : Taking high-specification automated sampling platforms in the industry as an example (such as the Logan DSC-800 / SYP series high-precision syringe pumps, or the Pharma Test DSR-M sampling workstation), all liquid-contacting components strictly adhere to high-purity 99.7% Al2O3 ceramic, PTFE, or PEEK inert materials. Combined with "isothermal media replacement" and "dual-loop backflushing and emptying" technologies, the carryover is minimized in the hardware physical structure.

5. Ensuring data integrity and mechanical verification : The accuracy of automated sampling must be based on precise syringe pump displacement correction, horizontal and vertical positioning of the sampling needle (XYZ axis positioning tolerance less than or equal to ±0.5 mm), and an audit trail framework that complies with FDA 21 CFR Part 11 to ensure that every sampling time stamp and sampling volume has complete data integrity.